Page de couverture de Surgical Pioneering Podcast

Surgical Pioneering Podcast

Surgical Pioneering Podcast

Auteur(s): Dr. Reza Lankarani
Écouter gratuitement

À propos de cet audio

 "Surgical Pioneering Surgical Frontiers: Pioneering Tech Transforming Surgical Care" Mission Statement: Welcome to Surgical Frontiers, a global nexus for surgeons, researchers, engineers, and healthcare innovators dedicated to advancing surgical care through groundbreaking technology. This group is not just a platform—it’s a movement. Here, we explore, debate, and champion the innovations redefining the art and science of surgery. From AI-driven diagnostics to robotic-assisted procedures, augmented reality (AR) surgical navigation, and bioengineered implants, we are the vanguard of a new era in medicine. If you’re driven by curiosity, excellence, and the relentless pursuit of better patient outcomes, you belong here. --- Our Core Values: 1. Innovation First Surgery is no longer confined to scalpels and sutures—it’s a fusion of biology, engineering, and data science. We prioritize discussions on emerging technologies (e.g., nanorobotics, AI-powered predictive analytics, 3D bioprinting) and their real-world applications. Share prototypes, clinical trial results, or even bold hypotheses—if it pushes boundaries, we want to hear it. 2. Collaboration Over Competition Breakthroughs happen when diverse minds unite. Surgeons, engineers, ethicists, and entrepreneurs are all equal stakeholders here. Whether you’re a seasoned robotic surgeon or a startup founder developing smart OR tools, your perspective matters. Let’s dismantle silos and co-create solutions. 3. Evidence-Based Excellence Pioneering doesn’t mean reckless. We demand rigor. Posts about new tools or techniques should be grounded in peer-reviewed research, clinical data, or transparent case studies. Anecdotes are welcome, but they must spark deeper inquiry, not replace it. 4. Patient-Centric Ethics Technology is a means, not an end. Every innovation must answer: How does this improve patient safety, accessibility, or outcomes? We encourage tough conversations about cost, equity, and unintended consequences. Glorifying "tech for tech’s sake" has no place here. 5. Global Perspective Surgical challenges vary wildly between a high-resource urban hospital and a rural clinic. Share insights from low-income regions, disaster zones, or underserved communities. Innovation thrives when we solve for the margins, not just the mainstream. --- What You’ll Find Here : - Breakthrough Technologies: Deep dives into robotics, AI/ML applications, AR/VR surgical training, IoT-enabled devices, and beyond. - Expert Insights: Q&As with thought leaders, interviews with FDA regulators, and AMAs (Ask Me Anything) with pioneers. - Case Studies: How a hospital in Kenya adopted portable robotic tools, or how a Boston team used AI to reduce post-op infections by 40%. - Ethical Debates: Should AI diagnose surgical complications? Who owns data from smart implants? - Resource Sharing: Grants, conferences (e.g., SAGES, AACR), and regulatory updates. --- Why Join? - Learn: Weekly summaries of JAMA Surgery or Annals of Surgery highlights. - Influence: Shape the future by beta-testing tools, joining global consortia, or advising startups. - Grow: Mentorship threads for residents, grants for underrepresented innovators, and hackathons. --- The Future We’re Building: Imagine a world where: - A surgeon in Mumbai receives real-time AR guidance from a specialist in Toronto. - Bioprinted organs eliminate transplant waitlists. - AI predicts surgical complications before the first incision. "This isn’t science fiction—it’s the horizon we’re sprinting toward." Let’s pioneer responsibly. Let’s operate fearlessly. Post, comment, and collaborate. The next surgical revolution starts here. — Reza Lankarani M.D Founder & Curator, Surgical Frontiers "Surgical Pioneering Surgical Frontiers: Pioneering Tech Transforming Surgical Care"

lankarani.substack.comReza Lankarani
Épisodes
  • "Vagilangelo, Innovation or Exploitation in Women’s Health Deep Dive Podcast"

    "Vagilangelo, Innovation or Exploitation in Women’s Health Deep Dive Podcast"
    Jul 13 2025
    The provided sources, primarily critiques from an OBGYN and health disparities researcher, Dr. Reza Lankarani, highlight significant concerns regarding the Vagilangelo® procedure and the broader landscape of cosmetic gynecology, particularly in the context of medical tourism and training in Arab countries. The central theme revolves around the tension between profit-driven healthcare and patient safety, arguing that the commercialization of uncertainty in women's health is exploitation, not innovation.1. The Vagilangelo® Procedure: Unsubstantiated Claims and Evidence DeficitThe Vagilangelo® procedure, marketed as a revolutionary vaginal rejuvenation technique, aims to restore "natural vaginal angulation" through internal suturing and platelet-rich plasma (PRP) injections. However, the sources assert that its claims are largely unsubstantiated by scientific evidence.Lack of Peer-Reviewed Validation: Despite claims of "77% satisfaction," Dr. Lankarani's critical review notes: "High satisfaction rates cited are anecdotal... Clinical trials comparing it to established methods would significantly strengthen its standing." The procedure lacks "zero randomized controlled trials," "no longitudinal safety data," and "absence of objective outcome measures (e.g., validated sexual function scales)."Unproven Biological Mechanisms: The efficacy of PRP for vaginal sensitivity lacks "tissue-specific evidence," and its growth factor concentrations and injection protocols are not standardized. This "scientific overreach" contrasts with established therapies that have documented effects.Inadequate Structural Correction: Marketing materials state Vagilangelo® provides "less tightening than traditional vaginoplasty," making it unsuitable for significant prolapse or laxity, positioning it as a "solution" for problems it cannot adequately address.Unquantified Risks: Unlike traditional surgeries with documented complication rates (e.g., vaginoplasty stenosis rates: 5–15% at 5 years), Vagilangelo® lacks published data on intraoperative risks, long-term safety, or pain management. The use of internal sutures poses theoretical risks of "urethral/bladder injury" and "nerve damage."2. The Exploitative Ecosystem: Medical Tourism and Predatory TrainingThe sources heavily criticize the "exploitative cosmetic surgery tourism" and "unethically trained practitioners" associated with procedures like Vagilangelo®, particularly targeting vulnerable women in low-resource settings like Bahrain.Medical Tourism's Hidden Costs: Bahrain's experience shows that its tertiary centers absorb significant costs (175,000 USD annually) treating complications from cosmetic tourism, mostly infections and implant failures. "All-inclusive packages" typically exclude meaningful postoperative care, leading to "patient abandonment" and an "economic drain" on local healthcare systems.Unethical Training Paradigms: The rise of "short-course 'fellowships'" (e.g., 3-5 day "certification" programs in Arab countries) enables this crisis. These programs lack "standardized curricula" and bypass the 1-2 years of supervised training required for legitimate surgical fellowships. They are accused of "targeting vulnerable populations" and allowing "underqualified surgeons operating on poor women," which is deemed "ethical malpractice."Commercialization of Insecurity: Vagilangelo® marketing is seen as violating core bioethical principles by prioritizing profit over documented clinical benefit. Patients cannot provide meaningful consent due to a lack of outcome data, and the high cash-pay cost ($3,000+) excludes low-income women who might need functional repair.3. Ethical Violations and Health DisparitiesThe commercialization of procedures without robust evidence is seen as contributing to global health inequity and ethical failures.Autonomy Violation: Patients cannot provide meaningful consent without comprehensive, evidence-based information on risks and benefits.Justice Failure: The high cost excludes low-income women who might benefit more from affordable, evidence-based functional repairs.Beneficence Abandonment: The emphasis on profit over documented clinical benefit is a betrayal of the medical principle of beneficence.Regressive Healthcare Subsidy: Public hospitals bear the burden of complications from offshore cosmetic procedures, effectively subsidizing a profit-driven industry.4. Policy Recommendations: Toward Ethical PracticeThe sources propose a multi-faceted approach to address these issues, emphasizing regulatory harmonization, patient safety integration, and ethical commercialization.Evidence and Regulation Reform: This includes an "immediate moratorium on Vagilangelo® marketing pending RCTs," standardization of outcome measures by professional bodies (e.g., ACOG/FIGO), and "FDA-equivalent oversight of PRP preparation protocols."Training and Equity Measures: Recommendations include a "global ban on <3-month cosmetic surgery 'fellowships'," mandatory ...
    Voir plus Voir moins
    14 min
  • Vagilangelo, Innovation or Exploitation in Women’s Health?

    Vagilangelo, Innovation or Exploitation in Women’s Health?
    Jul 11 2025
    Authored by Reza Lankarani MD Section 1: IntroductionCosmetic gynecology is a rapidly growing field, fueled by technological advances and increasing societal interest in aesthetic and functional modifications of female genital anatomy. Among these innovations, Vagilangelo® is heavily marketed as a revolutionary, minimally invasive vaginal rejuvenation technique promising to restore the "natural vaginal angle" disrupted by childbirth or aging, with purported benefits in sexual satisfaction and sensitivity.However, beneath its glossy promotional veneer lies a complex web of scientific uncertainties, ethical dilemmas, and health equity challenges. Today, we will dissect these layers with academic rigor and clinical insight to provide you, our listeners, with a nuanced understanding of Vagilangelo®’s place in modern gynecological practice.Section 2: Critical Scientific Weaknesses and Evidence GapsThe most significant issue surrounding Vagilangelo® is the stark absence of rigorous clinical evidence. Unlike well-established vaginal rejuvenation procedures documented in peer-reviewed journals such as The Journal of Sexual Medicine or the American Journal of Obstetrics and Gynecology, Vagilangelo® relies almost exclusively on manufacturer websites and patient testimonials for its claims. There are no Level I to III studies—meaning no randomized controlled trials, cohort studies, or even case series—to definitively prove its efficacy or safety.As Dr. Reza Lankarani, a respected clinical researcher, has emphasized, this lack of high-quality evidence is a glaring flaw that undermines the procedure’s credibility. In contrast, other less invasive modalities such as laser or radiofrequency (RF) therapies for vaginal rejuvenation have at least preliminary clinical data supporting their use.Furthermore, the biological rationale for the use of PRP injections in Vagilangelo® is problematic. Platelet-Rich Plasma has demonstrated efficacy in some medical fields, such as orthopedics, but its role in vaginal tissue regeneration and sensitivity enhancement remains unproven. Scientific literature, including recent studies published in journals like Cells in 2023, highlights the variability in PRP composition, the lack of standardized injection protocols, and conflicting results regarding its benefits for vaginal lubrication or sensitivity.Beyond these biological uncertainties, Vagilangelo® does not adequately address key structural issues. The procedure explicitly avoids correction of pelvic floor musculature or significant ligamentous laxity, which are often involved in pelvic organ prolapse or functional disorders. Marketing materials themselves acknowledge that Vagilangelo® offers less tightening than traditional vaginoplasty—rendering it unsuitable for patients with moderate to severe pelvic floor dysfunction.Finally, the risks associated with Vagilangelo® are frequently downplayed. Although marketed as “non-invasive,” internal suturing near delicate pelvic nerves and organs carries inherent risks such as suture erosion, chronic pain (dyspareunia), and urinary symptoms (dysuria). PRP injections may also cause complications like infection, scarring, or paradoxical pain. Post-procedural care often requires sexual abstinence for several weeks, mirroring surgical aftercare, yet standardized protocols for managing complications are lacking.---Section 3: Comparative Limitations Against Established AlternativesIn the landscape of vaginal rejuvenation, Vagilangelo® occupies an ambiguous niche. It is less invasive than traditional surgical options like vaginoplasty but more invasive than energy-based modalities such as laser or radiofrequency therapies.Energy-based devices have the advantage of inducing collagen remodeling with documented histological evidence and relatively low risk profiles, without the need for suturing. Vaginoplasty, on the other hand, is the gold standard for correcting severe anatomical defects, with decades of outcome and safety data.Vagilangelo® lacks the evidence base, functional scope, and risk-mitigation protocols of these traditional methods. It is neither a substitute for surgery nor a clearly superior alternative to energy-based treatments. This “middle ground” status complicates clinical decision-making and patient counseling.---Section 4: Ethical Concerns and Commercial ExploitationTurning to the ethical dimension, Vagilangelo® raises serious concerns about the commercialization of women’s health insecurities. The procedure is heavily marketed using terms like “revolutionary” and “groundbreaking,” which can create unrealistic expectations among vulnerable populations—particularly postpartum women who may be distressed by natural anatomical changes after childbirth.This marketing strategy violates ethical standards such as the American Medical Association’s Code of Medical Ethics §8.063, which stresses the importance of providing patients with realistic ...
    Voir plus Voir moins
    2 min
  • GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?

    GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?
    Jul 8 2025

    GLP-1 Agonists Versus Bariatric Surgery: A Paradigm Shift?

    1.1. Host: Obesity and diabetes management are seeing a seismic shift, Dr. Lankarani, with GLP-1 agonists like semaglutide making headlines. Is metabolic surgery becoming obsolete, or do these drugs complement existing surgical interventions?

    1.2. Guest: It's a critical juncture. While GLP-1 drugs offer noninvasiveness and 15–22% weight loss, bariatric surgery still outperforms in durability—delivering over 25% weight loss and diabetes remission in 80% of patients, as shown in STAMPEDE trial's 10-year data, which all these databases gatheredby by Dr Reza Lankarani, General Surgeon and Surgical Innovation Lead, Curator and Founder of Surgical Pioneering Newsletter and Podcast Series.

    1.3. Host: Yet, for some patients—especially those with BMI 30–35 or unwilling to undergo surgery—GLP-1s seem transformative. Real-world studies like SURMOUNT-4 highlight better adherence and lower complication rates. How should clinicians weigh these benefits against surgical options?

    1.4. Guest: Patient selection is key. Surgery addresses metabolic drivers beyond appetite suppression, but GLP-1s provide a cost-effective, accessible route for those at lower risk. The real challenge lies in balancing short-term drug trial data with proven surgical longevity.

    1.5. Host: So, as these therapies evolve, will we see more combination protocols or a clearer division between surgical and pharmacologic candidates?

    1.6. Guest: Combination strategies may soon emerge, particularly as we integrate longer-term GLP-1 outcomes. Ultimately, multidisciplinary teams must tailor approaches based on comorbidities, prior weight loss attempts, and patient preference.

    #generalsurgerycontroversies #surgicalethicsdebates #medicalmalpracticecases #invasivevsminimallyinvasivesurgery #surgicalinnovationcontroversies #patientsafetyinsurgery #surgicalguidelinesdebate #surgeonaccountabilityissues #healthcarepolicysurgery #surgicaltrainingcontroversies #postoperativecomplicationissues #surgicaltechnologydebates #surgeon-patientcommunication #surgicalriskmanagement #recentsurgicalscandals #surgicalPioneering glp-1 agonists #metabolic surgery #obesity management #weight loss strategies #type 2 diabetes treatment #bariatric procedures #gut hormones #semaglutide #liraglutide #wegovy #satiety regulation #appetite control #diabetes and obesity #future of obesity treatment #surgical vs medical obesity options



    Get full access to Reza Lankarani at lankarani.substack.com/subscribe
    Voir plus Voir moins
    1 min

Ce que les auditeurs disent de Surgical Pioneering Podcast

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.